- Home
- RERE vs CGEM Comparison
RERE vs CGEM Comparison
Compare RERE & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | CGEM |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.3M | 780.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RERE | CGEM |
|---|---|---|
| Price | $5.85 | $12.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | ★ 1.1M | 665.8K |
| Earning Date | 03-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $2,759,212,837.00 | N/A |
| Revenue This Year | $30.77 | N/A |
| Revenue Next Year | $25.01 | N/A |
| P/E Ratio | $35.67 | ★ N/A |
| Revenue Growth | ★ 27.95 | N/A |
| 52 Week Low | $2.00 | $5.68 |
| 52 Week High | $6.47 | $13.43 |
Technical Indicators
Market Signals| Indicator | RERE | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 56.93 |
| Support Level | $5.38 | $11.70 |
| Resistance Level | $6.00 | $13.43 |
| Average True Range (ATR) | 0.26 | 0.83 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 42.62 | 63.76 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.